Live News EQUITY M impact Jun 24, 2026, 12:31 PM UTC

WVE Initiates Phase 2a Trial

Wave Life Sciences initiates Phase 2a portion of INLIGHT trial of WVE-007 for obesity and cardiometabolic diseases

SQUAWKNEWS Updated Jun 24, 2026, 12:31 PM UTC

WVE - Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases